HUP0000432A3 - Insulin c-peptides - Google Patents

Insulin c-peptides

Info

Publication number
HUP0000432A3
HUP0000432A3 HU0000432A HUP0000432A HUP0000432A3 HU P0000432 A3 HUP0000432 A3 HU P0000432A3 HU 0000432 A HU0000432 A HU 0000432A HU P0000432 A HUP0000432 A HU P0000432A HU P0000432 A3 HUP0000432 A3 HU P0000432A3
Authority
HU
Hungary
Prior art keywords
insulin
peptides
Prior art date
Application number
HU0000432A
Other languages
English (en)
Original Assignee
Creative Peptides Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab
Publication of HUP0000432A2 publication Critical patent/HUP0000432A2/hu
Publication of HUP0000432A3 publication Critical patent/HUP0000432A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HU0000432A 1996-09-27 1997-09-26 Insulin c-peptides HUP0000432A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus

Publications (2)

Publication Number Publication Date
HUP0000432A2 HUP0000432A2 (hu) 2000-08-28
HUP0000432A3 true HUP0000432A3 (en) 2000-10-30

Family

ID=20404052

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000432A HUP0000432A3 (en) 1996-09-27 1997-09-26 Insulin c-peptides

Country Status (24)

Country Link
US (1) US6610649B2 (hu)
EP (1) EP0938503B1 (hu)
JP (1) JP2001500893A (hu)
KR (1) KR20000048643A (hu)
AT (1) ATE347562T1 (hu)
AU (1) AU741901B2 (hu)
BG (1) BG103362A (hu)
BR (1) BR9711573A (hu)
CA (1) CA2266416C (hu)
CZ (1) CZ108599A3 (hu)
DE (1) DE69737065T2 (hu)
DK (1) DK0938503T3 (hu)
ES (1) ES2278394T3 (hu)
HU (1) HUP0000432A3 (hu)
IL (1) IL129143A0 (hu)
IS (1) IS5008A (hu)
NO (1) NO991483L (hu)
NZ (1) NZ335231A (hu)
PL (1) PL332494A1 (hu)
RU (1) RU2206336C2 (hu)
SE (1) SE520392C2 (hu)
SK (1) SK39499A3 (hu)
TR (1) TR199900694T2 (hu)
WO (1) WO1998013384A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP5452843B2 (ja) * 2003-01-06 2014-03-26 エミスフィアー テクノロジーズ インコーポレイテッド 夜間の経口インスリン治療
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
US7557081B2 (en) * 2004-05-27 2009-07-07 Essential Skincare, Llc Alpha-1-acid glycoprotein for the treatment of diabetes
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
EP2054437A2 (en) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
US20100292132A1 (en) * 2007-09-11 2010-11-18 Dorian Bevec Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
GB0723250D0 (en) * 2007-11-28 2008-01-09 Univ Leeds Compositions and methods for reducing macrovascular complications in diabetic patients
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2334338A2 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of c-peptides
US8410049B2 (en) * 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
CN103119055A (zh) 2010-05-17 2013-05-22 塞比克斯公司 聚乙二醇化c肽
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
CN104220086A (zh) 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
RU2522897C1 (ru) * 2013-04-16 2014-07-20 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
CN104888201B (zh) * 2015-06-29 2018-04-27 齐锦生 用于防治糖尿病及其慢性并发症的肽类药物
EP3570875B1 (en) 2017-02-06 2022-07-06 Biotempt B.V. Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166913B (hu) * 1972-05-15 1975-06-28
JPS5210872B2 (hu) * 1973-07-14 1977-03-26
JPS55105653A (en) * 1978-10-02 1980-08-13 Shionogi & Co Ltd Tyrosyl c-peptides
CA1176158A (en) 1981-08-27 1984-10-16 Ronald E. Chance Pharmaceutical formulations comprising human insulin and human c-peptide
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) * 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5364757A (en) 1990-05-21 1994-11-15 Administrators Of The Tulane Educational Fund Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
DE69327239T2 (de) 1992-04-13 2000-05-11 Oklahoma Med Res Found Methoden and reagentien zur diagnose von autoantikörpern
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
AT400723B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
WO1996001846A1 (en) 1994-07-08 1996-01-25 Trustees Of Dartmouth College Proinsulin peptide compounds for detecting and treating type i diabetes
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU728186B2 (en) 1996-03-15 2001-01-04 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase

Also Published As

Publication number Publication date
IS5008A (is) 1999-03-23
DE69737065T2 (de) 2007-06-28
RU2206336C2 (ru) 2003-06-20
IL129143A0 (en) 2000-02-17
JP2001500893A (ja) 2001-01-23
CZ108599A3 (cs) 1999-08-11
BR9711573A (pt) 2000-01-18
SE9603533L (sv) 1998-03-28
CA2266416A1 (en) 1998-04-02
WO1998013384A1 (en) 1998-04-02
KR20000048643A (ko) 2000-07-25
TR199900694T2 (xx) 1999-06-21
NO991483D0 (no) 1999-03-26
AU741901B2 (en) 2001-12-13
BG103362A (en) 2000-05-31
CA2266416C (en) 2008-04-29
DE69737065D1 (en) 2007-01-18
US20020107175A1 (en) 2002-08-08
AU4391597A (en) 1998-04-17
PL332494A1 (en) 1999-09-13
SE9603533D0 (sv) 1996-09-27
ATE347562T1 (de) 2006-12-15
US6610649B2 (en) 2003-08-26
NO991483L (no) 1999-05-18
DK0938503T3 (da) 2007-04-10
ES2278394T3 (es) 2007-08-01
NZ335231A (en) 2000-11-24
SK39499A3 (en) 1999-10-08
HUP0000432A2 (hu) 2000-08-28
EP0938503B1 (en) 2006-12-06
EP0938503A1 (en) 1999-09-01
SE520392C2 (sv) 2003-07-01

Similar Documents

Publication Publication Date Title
HUP0002127A3 (en) Syringe
EP0979660A4 (en) SYRINGE
PL331901A1 (en) Syringe
PL331209A1 (en) Syringe
HUP0000432A3 (en) Insulin c-peptides
PL337324A1 (en) Stable insulin preparations
ZA981343B (en) Sulfonylurea-glitazone combinations for diabetes
GB2315414B (en) Syringes
GB9513967D0 (en) Insulin
EP0689052A3 (en) Standard insulin solution
GB9700789D0 (en) Syringe
GB9901108D0 (en) Anti-reuse syringe
GB9704660D0 (en) Oil-slick containment
HUP0000089A3 (en) Syringe
GB2325726B (en) Infusion device
SG81218A1 (en) Syringe
CA82511S (en) Cannula
GB9721136D0 (en) Syringes
GB9600178D0 (en) Syringe
GB9602205D0 (en) Syringe
GB9611986D0 (en) Syringe
GB2320195B (en) An improved syringe
GB2329335B (en) Medicament
GB9607355D0 (en) Syringes
GB9403442D0 (en) Syringe